The Quinism Foundation offers several services to organizations and individuals. Please contact us directly with questions related to these services.

Screening for Symptomatic Mefloquine Exposure

Organizations such as militaries and veterans’ agencies that care for individuals with past antimalarial use may bear a significant burden of unrecognized symptomatic exposure to mefloquine (previously marketed as Lariam®) within their populations. Unrecognized symptomatic mefloquine exposure – meaning the development of prodromal symptoms of mefloquine poisoning such as nightmares, insomnia, anxiety, depression, restlessness, or confusion, during past use of the drug – may, in turn, contribute to a risk of misattribution of symptoms of mefloquine poisoning to other potentially confounding disorders, such PTSD and TBI.

The Quinism Foundation offers the validated 2-question White River Mefloquine Instrument (WRMI-2) to aid organizations in screening their populations for a history of symptomatic mefloquine exposure.

The foundation recommends that all U.S. military veterans born since 1971 be screened for a history of symptomatic mefloquine exposure and that such screening, if positive, be accompanied by the taking of a mefloquine-focused history, particularly if the veteran is being considered for diagnoses of deployment-related neuropsychiatric disorders, including PTSD or TBI.

Please contact us for information on licensing the use of the WRMI-2 within your organization, or for further assistance in implementing a screening and training program.

Disability Evaluation Services for Veteran Compensation Claims

The Quinism Foundation offers independent medical evaluation services to U.S. veterans claiming disability from their exposure to mefloquine and related quinoline antimalarial drugs, including chloroquine (Aralen®) and tafenoquine (marketed as Krintafel® and Arakoda®).

U.S. veterans seeking Department of Veterans Affairs (VA) disability benefits have the opportunity to obtain a formal medical opinion (otherwise known as a “nexus letter”) directly through the foundation, at reduced fees to be subsided through the foundation’s charitable activities.

These services are offered under the direction of Dr. Remington Nevin, MD, MPH, DrPH, a former U.S. Army public health physician and Johns Hopkins-trained psychiatric epidemiologist and drug safety expert, who serves as Executive and Medical Director of The Quinism Foundation. Dr. Nevin has over a decade of experiencing writing authoritative independent medical opinion reports which have aided veterans in successfully obtaining up to 100% disability ratings for conditions conceded by the VA to be at least as likely as not the result of exposure to quinoline drugs, including mefloquine. Conditions which have been successfully awarded include anxiety and depressive disorders, sleep disorders including sleep apnea, paresthesias and radiculopathies, migraine and headache disorders, cranial neuropathies, and visual and vestibular disorders, among others. Dr. Nevin was recently recognized by a VA claims examiner as having “unique credentials, qualifications, and professional experience with regards to… mefloquine”.

U.S. and international veterans and their attorneys or accredited representatives with concerns related to mefloquine exposure are encouraged to contact us to discuss their case at no charge or for further information.